河北医科大学学报

• 论著 • 上一篇    下一篇

利拉鲁肽联合甘精胰岛素治疗2型糖尿病合并肥胖患者效果及对胰岛功能的影响

  

  1. 河北省石家庄市第一医院内分泌二科，河北 石家庄 050011
  • 出版日期:2019-06-25 发布日期:2019-06-19
  • 作者简介:金康（1985-），女，河北邯郸人，河北省石家庄市第一医院主治医师，医学硕士，从事内分泌疾病诊治研究。

Effects of Liraglutide combined with insulin glargine on the efficacy and islet function of type 2 diabetic patients with obesity#br#

  1. Department of Endocrinology， the First Hospital of Shijiazhuang， Hebei Province, Shijiazhuang 050011, China
  • Online:2019-06-25 Published:2019-06-19

HTML

PDF (PC)

166

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗评价利拉鲁肽联合甘精胰岛素治疗2型糖尿病合并肥胖患者效果及对胰岛功能的影响。
〖HTH〗方法〖HTSS〗〖KG*2〗选取2型糖尿病伴肥胖患者60例，性别不限，随机分为观察组和对照组各30例，2组均给予饮食、运动指导，并给予二甲双胍口服降糖治疗，对照组在此基础上给予甘精胰岛素皮下注射降糖治疗，观察组在对照组基础上给予利拉鲁肽皮下注射，治疗12周。观察体质指数(body mass index,BMI)、空腹血糖（fasting blood glucose,FBG）、餐后2 h血糖（2hour postprandial blood glucose,2 hPG）、糖化血红蛋白（glycated hemoglobin,HbA1c）、总胆固醇（total cholesterol，TC）、三酰甘油（triglyceride，TG）和胰岛素抵抗指数（insulin resistance index,HomaIR），比较治疗前后2组各项指标的变化和不良反应。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗后2组BMI、FBG、2 hPG、HbA1c、TC、TG、HomaIR均较治疗前下降，观察组上述指标均低于对照组，差异有统计学意义（P＜005）。
〖HTH〗结论〖HTSS〗〖KG*2〗利拉鲁肽联合甘精胰岛素治疗2型糖尿病合并肥胖患者效果良好，能显著改善糖脂代谢、减轻体重，同时改善糖尿病患者的胰岛细胞功能，值得临床推广。

关键词: 糖尿病, 2型, 肥胖症, 胰岛功能, 利拉鲁肽

Abstract: ［Abstract］ Objective〖HTSS〗〓To evaluate the effect of Liraglutide combined with insulin glargine on curative effect and islet function among type 2 diabetes mellitus population with obesity.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓ixty type 2 diabetes mellitus patients with obesity were randomly divided into trial group and control group with 30 patients in each group.Both groups received diet and exercise education and oral dimethyldiguanide treatment.Control group was given insulin glargine hypodermic injection whereas trial group had both Liraglutide and insulin glargine hypodermic injection for 12 weeks. Body mass index(BMI),fasting bloodglucose(FBG), 2hour postprandial blood glucose(2 hPG), glycated hemoglobin(HbA1c), total cholesterol(TC), triglyceride(TG),insulin resistance index(HomaIR) and side effects were compared before and after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓Compared with that before treatment, both groups showed a significant decrease of BMI, FBG, 2 hPG, HbA1c, TC,T G and HomaIR（P＜005) with a more significant decrease in trial group. After treatment, the above indicators in the observation group were lower than those in the control group, and the difference was statistically significant（P＜005）.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Liraglutide combined with insulin glargine has good therapeutic effect on obesity patients with type 2 diabetes mellitus. It can significantly improve the metabolism of glucose and lipid, reduce weight, and improve the function of islet cells in diabetic patients. It is worthy of clinical promotion.

Key words: diabetes mellitus, type 2, obesity, islet function, liraglutide

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发